---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-199173"
form_type: "8-K"
ticker: "EW"
cik: "0001099800"
company_name: "Edwards Lifesciences Corp"
filed_at: "2022-07-21T23:59:59+00:00"
generated_at: "2026-06-24T09:51:23.078730+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Edwards Lifesciences enters new $750M five-year revolving credit facility, replaces 2018 agreement

## Summary
- New $750M unsecured multi-currency revolving credit facility matures July 15, 2027.
- Pricing improved vs. 2018 facility; margin tied to leverage ratio or debt ratings.
- Facility includes options for increase up to $250M additional and multicurrency sub-limits.
- No amounts drawn as of July 15, 2022; proceeds for general corporate purposes and refinancing.
- Terminated the existing 2018 credit agreement on same date.

## SEC filing metadata
- accession: 0001193125-22-199173
- form_type: 8-K
- ticker: EW
- cik: 0001099800
- company_name: Edwards Lifesciences Corp
- filed_at: 2022-07-21T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1099800/000119312522199173/0001193125-22-199173-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1099800/000119312522199173/d383535d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-199173
- JSON: https://secwatch.observer/filing/0001193125-22-199173.json
- Plain text: https://secwatch.observer/filing/0001193125-22-199173.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.